Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to determine whether, GL-ONC1, an Oncolytic Virus, can safely be administered intravenously in patients with advanced solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis

NCT01443260

Peritoneal Carcinomatosis

COMPLETED PHASE1/PHASE2

Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions

NCT03141463

CIN 2/3 Cervical Cancer

COMPLETED PHASE1

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer

NCT05812677

Cervical Cancer Endometrial Cancer Advanced Cancer

RECRUITING EARLY_PHASE1

Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments

NCT04278326

HPV Infection Vaginal Cancer Cervical Dysplasia +1 more

TERMINATED NA

Cervical Cancer Screening of Postmenopausal Women in Low- and Middle-income Countries Using HPV Self-sampling and Triage by Genotyping and Cytology

NCT07244315

Cervical Cancer Screening HPV Infections Cervical Intraepithelial Neoplasia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In preclinical studies, GL-ONC1 an oncolytic vaccinia virus, has shown the ability to preferentially locate, colonize and destroy tumor cells. This study seeks to evaluate the safety profile of an attenuated vaccinia virus when administered intravenously to patients with advanced solid tumors. The study also seeks to detect virus delivery to primary and/or metastatic tumors, including evaluation of viral delivery by fluorescence imaging (GFP expression); whether anti-vaccinia virus immune response occurs; and will record evidence of any anti-tumor activity. For Cohorts 8 and Expansion Cohort 1B, CTC counts, virus-encoded marker gene analysis and Dynamic Contrast (DCE-MRI) MRI imaging will be used to evaluate tumor micro-circulation in vivo. These measures will be evaluated for their potential predictive value of survival outcomes, and to evaluate any correlation of such pharmacodynamic and response rate indicators in the GL-ONC1 treatment context.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancers (Solid Tumors)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GL-ONC1

a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of histologically or cytologically documented, advanced stage, primary or metastatic solid tumors refractory to standard therapy or for which no curative standard therapy exists.
* Evidence of measurable or evaluable disease.
* Age must be ≥ 18 years.
* All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedures must have resolved to Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) Grade ≤ 1. Surgery must have occurred at least 28 days prior to study enrolment.
* Chemotherapy or radiotherapy (other than small-field palliative radiotherapy), immunotherapy and/or hormonal therapy must have been received \> 28 days prior to receiving study drug. Subjects may continue to receive LHRH analogue therapy for prostate cancer in face of rising PSA. Bisphosphonates and anticoagulants are permitted.
* ECOG Performance Score ≤ 1.
* Life expectancy of at least 3 months.
* Required baseline laboratory data include:

* Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9 \[SI units 10\^9/L\]
* Platelets ≥ 100 x 10\^9 \[SI units 10\^9/L\]
* Haemoglobin ≥ 9.0 g/dL \[SI units gm/L\]
* Serum creatinine ≤ 1.5 x upper limit of normal (ULN)
* Bilirubin ≤ 1.5 x ULN
* AST/ALT ≤ 2.5 x ULN or ≤ 5 x ULN in the presence of liver metastases
* Ejection fraction of ≥50% by MUGA or ECHO.
* Signed informed consent indicating that the subject is aware of the neoplastic nature of his or her disease and has been informed of the procedures to be followed, the experimental nature of the therapy, the alternatives and the potential benefits, side effects, risks, and discomforts.
* Willing and able to comply with scheduled visits, treatment plan, and laboratory tests.
* Female patients must have a negative pregnancy test within five days prior to treatment.
* Female patients of childbearing potential who are not surgically sterile or postmenopausal and male patients who are not surgically sterile must agree to use highly effective contraception. Barrier methods for contraception must be applied during the treatment period and up to day 60 after the last virus application. The patient must agree to sign his or her consent on this particular inclusion criterion.

1. Diagnosis of histologically or cytologically documented, advanced stage solid tumor (e.g., primary or metastatic breast, prostate or colorectal cancer) refractory to standard therapy or for which no curative standard therapy exists.
2. Evidence of measurable or evaluable disease.
3. Disease that can be safely serially biopsied.
4. Circulating tumor cell count \> 10 for analyses of tumor cell viral delivery.

Exclusion Criteria

* Prior therapy with a cytolytic virus of any type.
* Concurrent therapy with any other investigational anticancer agent.
* Concurrent vaccines or immunotherapy during, and for 30 days before or after, study therapy.
* Concurrent antiviral agent active against vaccinia virus (e.g. cidofovir, vaccinia immunoglobulin, imatinib, ST-246) during course of study.
* Patients vaccinated with vaccinia virus within the past 10 years.
* Patients with known brain metastases: due to poor prognosis and risk of developing progressive neurological dysfunction that would confound the evaluation of neurological or other adverse events.
* Patients with known allergy to ovalbumin or other egg products.
* Patients with immune system disorders or who are receiving immunosuppressive therapy or any steroids.
* Patients with clinically significant dermatological disorders, e.g. eczema or psoriasis, or any unhealed skin wounds or ulcers, as assessed by the principal investigator during the screening and during the study.
* Patients with fevers, or any systemic infections, including known HIV infection, hepatitis B or C.
* Prior splenectomy.
* Previous organ transplant.
* Pregnant or breast-feeding women.
* Clinically significant cardiac disease (New York Heart Association, Class III or IV) including pre-existing arrhythmia, uncontrolled angina pectoris or myocardial infarction within one year prior to study entry, or grade 2 or higher compromised left ventricular ejection fraction (as determined by MUGA).
* Dementia or altered mental status that would prohibit informed consent.
* Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the principal investigator, would make the subject inappropriate for this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No